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Beneficial effects of murtilla extract 
and madecassic acid on insulin 
sensitivity and endothelial function 
in a model of diet-induced obesity
Jorge Arancibia-Radich1, Raquel González-Blázquez2, Martín Alcalá3, Miriam Martín-
Ramos4,5, Marta Viana3, Silvia Arribas6, Carla Delporte1, María S. Fernández-Alfonso4,5, 
Beatriz Somoza  2 & Marta Gil-Ortega2
Infusions of murtilla leaves exhibit antioxidant, analgesic, and anti-inflammatory properties. Several 
compounds that are structurally similar to madecassic acid (MA), a component of murtilla leaf extract 
(ethyl acetate extract, EAE), have been shown to inhibit protein tyrosine phosphatase 1B (PTP1P). 
The aim of this study was to evaluate if EAE and two compounds identified in EAE (MA and myricetin 
[MYR]) could have a beneficial effect on systemic and vascular insulin sensitivity and endothelial 
function in a model of diet-induced obesity. Experiments were performed in 5-week-old male C57BL6J 
mice fed with a standard (LF) or a very high-fat diet (HF) for 4 weeks and treated with EAE, MA, MYR, 
or the vehicle as control (C). EAE significantly inhibited PTP1B. EAE and MA, but not MYR, significantly 
improved systemic insulin sensitivity in HF mice and vascular relaxation to Ach in aorta segments, due 
to a significant increase of eNOS phosphorylation and enhanced nitric oxide availability. EAE, MA, 
and MYR also accounted for increased relaxant responses to insulin in HF mice, thus evidencing that 
the treatments significantly improved aortic insulin sensitivity. This study shows for the first time that 
EAE and MA could constitute interesting candidates for treating insulin resistance and endothelial 
dysfunction associated with obesity.
Ugni molinae Turcz, Myrtaceae (Myrtus ugni Mol.) is a Chilean native species commonly known as murtilla, 
murta or uñi that grows in the wild in southern Chile. Murtilla is a bush approximately 1.5 m high that can some-
times reach 2 m. Its fruits are eaten fresh and used in homemade jam, syrup, desserts, and liquor1,2. According to 
popular culture, murtilla has anti-inflammatory and antioxidant properties, among others1,3. It has been proven 
that the regular intake of infusions of murtilla leaves increases plasmatic antioxidant capacity, due to the high 
number of polyphenols, heterosides (rhamnoside, xylosides, and glucosides) of flavonols such as quercetin, myri-
cetin, and kaempferol, in addition to genins, such as quercetin, myricetin and epicatechin4–6. Other researched 
properties of murtilla leaves are antimicrobial action6,7 and inhibition of enzymes involved in the control of 
glycaemia such as α-amylase and α-glycosidase8. Our previous studies carried out with wild murtilla leaves have 
shown that the ethyl acetate extract (EAE) and the ethanolic extract have anti-inflammatory and analgesic prop-
erties9. Moreover, we have contributed to the knowledge of several triterpenoid acids present in murtilla leaves, 
such as: oleanolic, ursolic, betulinic, alphitolic, corosolic, maslinic, asiatic, and madecassic acid10–12.
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It is well known that obesity constitutes an independent risk factor for the development of several cardiometa-
bolic disorders13,14. An association between obesity and the development of both insulin resistance and endothe-
lial dysfunction has been described even in early stages of obesity14–18. Recent studies aimed at ameliorating 
cardiometabolic disorders associated with obesity have highlighted protein tyrosine phosphatase 1B (PTP1B) 
as a potential target to improve not only insulin sensitivity, but also endothelial dysfunction19. In this regard, 
selective deficiency of PTP1B in the liver significantly improves insulin sensitivity, thus leading to complete pro-
tection against obesity-induced endothelial dysfunction20. Moreover, several inhibitors of PTP1B, like CX0800521 
or Norathyriol22, have been found to significantly improve insulin sensitivity in murine models of diet-induced 
obesity (DIO). Interestingly, several pentacyclic acid triterpenoids, with a similar chemical structure to madecas-
sic acid (MA), have been observed to inhibit PTP1B activity, thus improving insulin sensitivity and stimulating 
glucose uptake23. Moreover, it has been suggested that MA could have antidiabetic effects, though further studies 
are required24.
A very recent study has suggested that murtilla fruit extract exhibits vasodilatory activity mediated by nitric 
oxide (NO) release in aortic rings from normal-weight Sprague Dawley rats25.
The hypothesis of this study is that the EAE of murtilla leaves corresponding to genotype 19-1 (EAE) has a 
beneficial effect on insulin resistance through the inhibition of PTP1B and on endothelial dysfunction through 
an increase in NO availability in a murine DIO model. In addition, since MA and myricetin (MYR) are two of the 
compounds identified in EAE9, we also wondered if the potential effects mediated by EAE could be attributed to 
either MA and/or MYR. Therefore, the aim of this study was to evaluate whether a 4-week treatment with either 
EAE, MA, or MYR modifies: i) body weight and adiposity, ii) systemic insulin sensitivity, iii) endothelial function, 
and iv) vascular insulin sensitivity.
Materials and Methods
Animals and dietary treatments. Four-week old male C57BL/6 J mice (Charles River, Spain) weigh-
ing 16–18 g were housed under controlled light (12-hour light/dark cycles from 8 am to 8 pm) and temperature 
(22–24 °C) conditions with standard food and water ad libitum. After one week of acclimation, animals with 
similar average body weight were divided into two groups, housed five per cage, and assigned to a control low-fat 
diet (LF) or to a high-fat diet (HF). Control LF (D12450B, 10 kcal % fat, 72 kcal % carbohydrates, and 18 kcal % 
protein; 3.76 kcal/g) and HF (D12451, 62 kcal % fat, 20 kcal % carbohydrates, and 18 kcal % protein; 5.1 kcal/g) 
diets were supplied by Test Diet (UK). All animals had free access to food for 4 weeks. In addition, animals 
were injected daily with murtilla extract (EAE, 20 mg/kg), madecassic acid (MA, 20 mg/kg), myricetin (MYR, 
20 mg/kg) or saline with 1% DMSO (vehicle of the active ingredients and the extract) intraperitoneally (i.p), thus 
generating 8 different groups LF-C, LF-EAE, LF-MA, LF-MYR, HF-C, HF-EAE, HF-MA, and HF-MYR. On 
the last day, mice were weighed and euthanized by decapitation at 9 am. Blood was collected in chilled EDTA-
coated polypropylene tubes. Plasma samples were stored at −80 °C for biochemical determinations. Perirenal 
(PR-AT), subcutaneous (SC-AT), and mesenteric adipose tissues (Mes-AT) were dissected, weighed, and their 
weight was normalized by tibia length. Thoracic aortas were used for both vascular function and RT-qPCR stud-
ies. The study conforms to the Guide for the Care and Use of Laboratory Animals published by the US National 
Institute of Health (NIH publication No.85–23, revised in 2011) and was approved by the Ethics Committee of 
the Universidad Complutense de Madrid.
Intraperitoneal glucose tolerance test (GTT). During the last week of dietary treatment, mice were 
fasted for 6 h before the glucose load (i.p. bolus of 1 g/kg at time 0). Blood glucose level was measured immediately 
at 0, 15, 30, 45, 60, 90, and 120 min after injection. At the indicated times, blood samples were drawn from the 
tail vein of conscious mice for glucose determination with an Accu-Chek Aviva glucometer (Roche Diagnostics, 
Germany).
PTP1B inhibition assay in vitro. The protein tyrosine phosphatase 1B (PTP1P) inhibition assay 
was adapted from the method previously described by Na et al.26. Briefly, PTP1B activity was assessed using 
p-nitrophenyl phosphate (pNPP) as a substrate that is hydrolyzed by PTP1B to p-nitrophenol. Reactions were 
performed in 96-well plates. To each well, 12 mM pNPP and 0.1 μg of recombinant PTP1B (expressed in E. Coli) 
were added in a buffer containing 50 mM HEPES, 150 mM NaCl and 5 mM dithiothreitol (DTT) with or without 
the murtilla extract (EAE, 2 μg/ml) diluted in 12.5% DMSO. After 30 min of incubation at 37 °C, the reaction was 
stopped with 5 M NaOH. The amount of p-nitrophenol was estimated by measuring the absorbance at 405 nm. 
The non-enzymatic hydrolysis of 12 mM pNPP was corrected by the increase in absorbance measured at 405 nm 
in the absence of PTP1B.
RNA extraction and real-time PCR (RT-qPCR). Total RNA was isolated from the aorta using Trizol 
Reagent (Invitrogen, Spain). The samples were processed using an RNeasy Mini Kit (Qiagen, Spain). The 
concentration, purity, and integrity of RNA was assessed with NanoVue (GE Healthcare, Germany). Reverse 
transcription was performed on 500 ng of RNA with an iScript cDNA synthesis kit (BioRad, CA) using ran-
dom hexamer primers. Optimal annealing temperature and amplicon sizes were checked for each pair of 
primers. RT-qPCR analyses were performed in a CFX96 Instrument (BioRad, CA). The primer sequence 
for the PTP1B gene, Ptpn1 (accession number NM_011201.3) was 5′-GGAGACCTGTGGGGATGA-3′ 
(forward) and 5′-TCAGTGTCTGGACTCATGCTG-3′  (reverse) and for the housekeeping gene, 
Tbp (accession number NM_013684.3), 5′-ACCCTTCACCAATGACTCCTATG-3′ (forward) and 
5′-TGACTGCAGCAAATCGCTTGG-3′ (reverse). A total of 6.25 ng of cDNA from 4 samples of each group were 
run in triplicate and the mRNA levels were determined using intron-skipping primers, TBP as a housekeeping 
gene, and SYBR Green Master Mix (Applied Biosystems, CA).
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Vascular reactivity in isolated aortic arteries cleaned of PVAT. Vascular reactivity experiments were 
performed as previously described27. Briefly, aortic rings of 2–3 mm in length were given an optimal resting 
tension of 1.5 g, which was readjusted every 15 min for a 40-min equilibration period. Before starting the exper-
iment, rings were contracted with 75 mM KCl to assess their contractility. Contractile responses were assessed 
by the incubation of aortic segments with phenylephrine (Phe, 10−8 to 10−6M). Endothelial integrity was ana-
lyzed by addition of acetylcholine (Ach, 10−9 to 10−4M) to segments pre-contracted with Phe (10−7 to 10−6M 
to reach an equivalent tone between groups). The nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl 
ester (L-NAME, 10−4M) was pre-incubated for 20 min before adding Phe (10−7 to 10−6M). NO contribution was 
assessed by calculating the percentage of inhibition of Ach-induced relaxations by L-NAME. Relaxant responses 
to insulin were determined by addition of insulin (10−10–10−5M) to segments pre-contracted with Phe (10−7 to 
10−6M). Endothelium-independent relaxation was analyzed by addition of sodium nitroprusside (SNP, 10−12–
10−5M) to segments pre-contracted with Phe (10−7 to 10−6M).
Cell culture experiments. Bovine aortic endothelial cells (BAECs) were obtained from the European col-
lection (ECACC; Sigma-Aldrich, Spain). BAECs were cultured in complete medium (Dulbecco’s modified Eagle’s 
medium [DMEM] with 10% fetal bovine serum [FBS], L-glutamine [2·10−3M], penicillin [100 U/mL], and strep-
tomycin [100 μ/mL] from LONZA, USA) and maintained at 37 °C in a humidified atmosphere consisting of 5% 
CO2 and 95% air. All the experiments were performed in confluent cells (90%), between passages 3 and 6 and 
cultured in DMEM and 0.1% of bovine serum albumin (BSA), thus being deprived of serum for 20 h. Under 
these conditions, cells were treated with insulin (5·10−7M) for 10 min, with EAE (40 μg/mL) or MA (5·10−4M) 
for 15 min, or nothing as a control. After these incubations, cells were briefly washed with ice-cold PBS and 
were then scraped in lysis buffer containing 0.42 mM NaCl, 1 mM Na4P2O7, 1 mM dithiothreitol, 20 mM HEPES, 
20 mM NaF, 1 mM Na3VO4, 1 mM EDTA, 1 mM EGTA, 20% glycerol, 2 mM phenylmethylsulfonyl fluoride, 1 µl/
ml leupeptin, 1 µl/ml aprotinin, and 0.5 µl/ml Tosyl-L-lysyl-chloromethane hydrochloride. Cells lysates were cen-
trifuged at 17.000xG for 20 min at 4 °C and the supernatants were used for Western blot studies.
Confocal microscopy experiments. BAECs were directly plated on 24 mm2 glass cover slips and subse-
quently used for evaluating endogenous NO production. Cells, previously deprived of serum and treated with 
insulin, EAE, or MA, as previously described (see cell culture experiments), were incubated with a fluorescent NO 
indicator 4,5-diaminofluorescein diacetate (DAF-2DA, 10−5M; Sigma-Aldrich, USA) for 30 min. Thereafter, cells 
were washed with cold PBS and fixed in paraformaldehyde (PFA) at 4%. Nuclei were stained by incubation with 
4′,6-diamino-2-phenylindole (DAPI, 1:500 from stock 5 mg/ml; Molecular Probes, USA) for 15 min at room tem-
perature in the dark and cells were washed with PBS. The cover slips with BAECs were mounted in a glycerol/PBS 
solution (Citifluor, VWR International, Spain) and analyzed by confocal microscopy as previously described28. 
From each culture, a minimum of 3 randomly selected images were captured with a LEICA SP5 confocal micro-
scope (Leica Microsystems) using the 488 nm/530 nm (DAF-2DA, NO) and 405 nm/410–475 nm (DAPI, nuclei) 
filters with a x20 objective.
Western blot analyses. p-AKt/AKt and p-eNOS/eNOS expression was determined in cells treated with 
insulin, EAE, or MA by Western blot, as previously described29. Briefly, 30 µg protein samples were separated 
by 10% SDS-PAGE gels. Primary antibodies against e-NOS (BD Transduction Laboratories, UK; 1:1000 final 
dilution), p-eNOS (Ser-1177) (Cell Signalling Technology, USA; 1:500 final dilution), AKt (Cell Signalling 
Technology, USA; 1:500 final dilution) and p-AKt (Ser-473) (Cell Signalling Technology, USA; 1:1000 final dilu-
tion) were applied overnight at 4 °C. After washing, appropriate secondary antibodies (anti-rabbit IgG-peroxidase 
conjugated) were applied for 1 h. Blots were washed, incubated in commercial enhanced chemiluminescence 
reagents (ECL, Amersham Bioscience, UK) and analyzed with ChemiDoc (BIO-RAD, Spain). To prove equal 
loadings of samples, blots were re-incubated with β-actin antibody (Sigma-Aldrich, Spain). Expression values of 
p-AKt and peNOS were normalized with AKt and eNOS, respectively.
Chemicals. Ach was dissolved in saline, Phe and SNP in 0.01% ascorbic acid/saline and L-NAME and insulin 
in distilled water (Sigma-Aldrich, USA). Madecassic acid, myricetin (Santa Cruz Biotechnology) and murtilla 
extract were dissolved in DMSO.
Data analyses. All values are given as mean ± SEM and n denotes the number of animals used in each 
experiment. Statistical significance was analyzed using one-way or two-way analysis of variance (ANOVA) 
followed by Bonferroni or Newman-Keuls post-hoc test for comparison between groups. A value of p < 0.05 
was considered statistically significant. In vascular reactivity experiments, contractions are expressed as the 
percentage of contraction elicited by 75 mM KCl. Relaxations are expressed as the percentage of previous Phe 
contraction. The maximum response (Emax values) was calculated by nonlinear regression analyses of each indi-
vidual concentration-response curve. The area under the curves (AUC) were calculated from the individual 
concentration-response curve plots (GraphPad Software, USA).
Results
Body weight, adiposity, and glucose tolerance. After 4 weeks of diet, HF-C mice exhibited a sig-
nificantly higher body weight than the control group (LF-C:22.8 ± 0.6 g vs. HF-C:24.3 ± 0.7, p < 0.05). Neither 
treatment with EAE nor with MYR modified body weight after the HF diet (Table 1). However, the treatment with 
MA significantly reduced the body weight of HF mice to the level of the LF-C group (HF-MA:22.3 ± 0.8; p < 0.05 
compared to HF-C). These changes were not attributable to differences in food intake, since it was similar in all 
groups (Supplementary Figure 1). No effects of treatment were observed on the body weight of LF groups.
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The amount of both PR-AT and SC-AT was higher in HF-C animals than in LF-C, but no differences were 
detected in Mes-AT (Table 1). Treatment with EAE or MA did not modify the amount of SC-AT and PR-AT in HF 
or LF animals. However, MYR significantly reduced the amount of SC-AT in HF mice (p < 0.05). Nevertheless, 
treatment did not affect animal growth as assessed by tibial length (Table 1).
As shown in Fig. 1, the GTT area under the curve (AUC) was significantly higher in HF-C animals than in the 
LF-C group, which suggests that there was significant glucose intolerance in HF-C mice (Fig. 1). The treatment 
with MA (Fig. 1C) significantly improved the glucose tolerance in HF mice. Indeed, HF-MA mice even exhibited 
similar GTT AUC to LF-C mice (Fig. 1D). The treatment with EAE induced a faster reduction in glucose levels 
in HF than in HF-C, as shown in glucose levels 90 min after glucose overload (HF-C: 228.8 ± 12.3 vs. HF-EAE: 
181.8 ± 14.7, p < 0.05) (Fig. 1A). Nevertheless, the effect was not strong enough to reflect differences in the AUC 
(Fig. 1B). The treatment with MYR did not modify glucose tolerance (Fig. 1E,F).
Inhibition of PTP1B by EAE in vitro and PTP1B expression in the murine aorta. EAE, used at a 
concentration of 2 μg/mL, significantly inhibited the PTP1B, with 97.2 ± 0.9% percentage of inhibition. This result 
suggests a role for EAE in the regulation of both insulin sensitivity and glucose uptake.
In addition, since insulin sensitivity was significantly impaired in HF mice and relaxant responses to insulin 
were compromised in aortic segments from HF mice, we also evaluated PTP1B mRNA expression in aorta. As 
expected, PTB1B expression was significantly enhanced in aorta segments by the HF diet (p < 0.05), except in HF 
mice treated with MA, which exhibited similar values to the LF-C group (Fig. 1G).
Treatment with EAE or MA improved endothelial function in HF mice. Endothelial function 
was evaluated by analyzing endothelium-dependent relaxations to Ach (10−9 to 10−4 M) in aortic segments 
pre-constricted with Phe. Relaxant responses to Ach were significantly lower in aortic segments from HF-C mice 
than those from LF-C, which evidences an endothelial dysfunction in aortas from HF mice (Emax LF-C:81.5 ± 1.5 
vs. Emax HF-C:64.1 ± 4.2, p < 0.001, Fig. 2 and Table 2). In HF mice, treatment with EAE (Fig. 2B) and MA 
(Fig. 2E) restored Ach-induced relaxation, which showed similar values to the LF-C group (Fig. 2A,D, respec-
tively). However, MYR did not modify the response to Ach in LF or HF mice (Fig. 2G,H).
To assess whether the treatment with EAE or MA increased NO availability, aortic rings were pre-incubated 
with L-NAME (10−4M). In the presence of L-NAME, Ach-induced relaxations were significantly reduced in both 
LF-C and HF-C groups (Emax LF-C:16.5 ± 3.2 vs. Emax HF-C:13.0 ± 5.4, Fig. 2). Nevertheless, the percentage of 
inhibition elicited by L-NAME (calculated from the difference between the AUC in the presence and absence of 
L-NAME that indirectly indicates ACh-induced NO release) was lower in the HF-C group (73%) than in the LF-C 
group (83.5%) (Fig. 2C, see NO contribution in white). In addition, the treatment with both EAE and MA, but not 
with MYR, significantly increased Ach-induced NO release to reach normal values (% of inhibition in HF-EAE: 
83%, Fig. 2C; % of inhibition in HF-MA: 88.8%, Fig. 2F; % of inhibition in HF-MYR: 74.6%, Fig. 2I).
Moreover, smooth muscle sensitivity to NO, assessed with concentration-response curves to a NO donor SNP 
(10−12–10−5M) was not modified by the HF diet or by EAE or MA. However, HF mice treated with MYR exhib-
ited a significant reduction of relaxation elicited by SNP (Supplementary Figure 2).
To assess the effects of treatments on vascular contractility, concentration-response curves to Phe 
(10−8M–10−6M) were performed in aortic segments. Contractile responses to Phe were significantly smaller in 
the HF-C group than in the LF-C group (p < 0.05). In addition, treatment with EAE, MA, or MYR reduced 
Phe-induced contractions in HF animals (p < 0.05, p < 0.05, and p < 0.001, respectively compared to the HF-C 
group, Fig. 3).
Treatment with EAE, MYR, or MA enhanced relaxant responses to insulin in HF mice. To ana-
lyze the effect of treatments on aortic insulin sensitivity, we performed concentration-responses curves to insulin 
(10−10M-10−5M) in vessels pre-constricted with Phe. As shown in Fig. 4, relaxant responses to insulin were signif-
icantly compromised in aortic segments from HF-C mice (p < 0.05) compared to the LF-C group. However, when 
treated with EAE, MA, or MYR, aortic segments from HF mice exhibited similar relaxant responses to insulin to 
the LF-C group (Fig. 4A–C).
Both EAE and MA increased NO availability in BAECs through AKT and eNOS phosphorylation. 
Since both EAE and MA, but not MYR, significantly enhanced NO availability in the murine aorta (Fig. 2), we 
next analyzed by confocal microscopy whether EAE or MA might directly induce NO production in BAECs 
treated with EAE or MA. Insulin was used as a positive control. As expected, fluorescence intensity and thus NO 
LF-C LF-EAE LF-MA LF-MYR HF-C HF-EAE HF-MA HF-MYR
Body weight (g) 22.8 ± 0.6 22.3 ± 0.5 23.0 ± 0.6 21.7 ± 0.9 24.3 ± 0.7* 24.5 ± 1.2 22.8 ± 0.8 23.5 ± 0.6
PR-AT (mg/mm) 3.9 ± 0.5 3.6 ± 0.3 2.8 ± 0.2 2.9 ± 0.3 6.8 ± 1.1* 6.5 ± 1.3 6.5 ± 0.7 4.8 ± 1.1
SC-AT (mg/mm) 15.3 ± 1.6 15.1 ± 0.7 12.6 ± 0.7 17.0 ± 1.6 20.1 ± 1.9* 21.2 ± 2.7 17.1 ± 1.3 14.6 ± 2.1#
Mes-AT (mg/mm) 3.8 ± 0.6 4.1 ± 0.6 3.0 ± 0.2 2.4 ± 0.2 4.0 ± 0.9 4.2 ± 0.9 4.5 ± 0.3 3.1 ± 0.3
Tibial length (mm) 22.3 ± 0.2 22.3 ± 0.2 22.5 ± 0.3 22.0 ± 0.3 22.4 ± 0.2 22.4 ± 0.4 22.2 ± 0.4 22.1 ± 0.4
Table 1. Effect of dietary treatment on body weight and adiposity. Adipose tissue weights were normalized 
using the tibial length, which was not modified by the high-fat diet. Data on body and adipose tissues are 
expressed as mean ± SEM of 5 determinations per group. *p < 0.05 compared with control group LF; #p < 0.05 
compared with control group HF.
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availability was significantly enhanced by the treatment with EAE, MA, or insulin compared with the controls 
(Fig. 5).
In addition, Western blot studies revealed that treatment with EAE or MA significantly increased AKt phos-
phorylation in BAECs, as shown in Fig. 6A (p < 0.01) and 6C (p < 0.05), respectively, compared to the control 
group and similarly to BAECs treated with insulin. Moreover, eNOS phosphorylation (p-eNOS-Ser1177) was also 
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Figure 1. GTT (A,C,E) and AUC during the GTT (B,D,F) in LF and HF mice treated or not with EAE, MA, or 
MYR, respectively. (G) Diagram bars show PTP1B mRNA expression in aortas from LF and HF mice treated or 
not with EAE or MA. Data are expressed as mean ± SEM of 5 determinations per group. *p < 0.05, **p < 0.01, and 
***p < 0.001 compared with LF-C (A,C,E) or the matched group (B,D,E,G). ###p < 0.001 compared with HF-C.
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enhanced by both EAE and MA compared with the controls (Fig. 6B [p < 0.05] and 6D [p < 0.01], respectively), 
and reached similar values to those mediated by insulin. Nevertheless, combined treatment with EAE or MA and 
insulin did not enhance the effect observed with single treatments (Fig. 6B,D).
Discussion and Conclusions
In this study, we demonstrate for the first time that murtilla extract (EAE) inhibits PTP1B activity and signifi-
cantly improves i) systemic glucose tolerance, ii) endothelial function, and iii) vascular insulin sensitivity in a 
DIO model in mice. The amelioration of vascular function induced by treatment with EAE in HF mice was found 
to be due to an increase in NO bioavailability. Moreover, we show that benefits of EAE in obesity could be directly 
mediated by MA, at least in part, since MA is one of the compounds identified in EAE and it induces similar 
effects to EAE.
Several studies performed in different models of DIO in mice18,30,31, rats32,33, and even observational studies 
in humans14,34,35 have largely demonstrated that cardiometabolic disorders emerge during the onset of obesity. In 
fact, it has been described that several disorders like insulin resistance or endothelial dysfunction might appear 
even at early stages in the development of obesity14,18,30–35. Because insulin-sensitizing drugs are limited, it is a 
priority to identify new potential candidates. In this regard, recent studies aimed at ameliorating cardiometabolic 
disorders associated with obesity have highlighted PTP1B as a potential target to improve not only insulin sen-
sitivity, but also endothelial dysfunction19. Indeed, several inhibitors of PTP1B, like CX0800521 or Norathyriol22, 
have been found to significantly improve insulin sensitivity in murine models of DIO. Here, we have demon-
strated the ability of EAE to inhibit PTP1B activity. In addition, glucose tolerance was improved in HF animals 
treated with EAE, though this effect was not as strong as the effect induced by MA. Interestingly, several com-
pounds with a similar chemical structure to MA have been found to inhibit PTP1B23. A potential antidiabetic 
effect of MA24 has also been described. As MA is indeed one of the components of EAE, we could speculate that 
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Figure 2. Cumulative concentration-response curves to acetylcholine (10−9–10−4M) in aortic segments pre-
incubated or not with L-NAME (10−4M) from LF mice treated or not with EAE (A), MA (D), or MYR (G) 
and HF mice treated or not with EAE (B), MA (E), or MYR (H). Bar diagrams showing AUC from cumulative 
concentration-response curves to acetylcholine (10−9–10−4M) in aortic segments from mice treated or not 
with EAE (C), MA (F), or MYR (I). The percentage of inhibition elicited by L-NAME and shown in white bars 
indirectly reflects the NO contribution to ACh-induced relaxant responses. Data are expressed as mean ± SEM 
of 5 determinations per group. ***p < 0.001 compared with the corresponding control group; ###p < 0.001 
compared with the HF-C group; $p < 0.05, $$$p < 0.001 compared with LF-C L-NAME; &p < 0.05 compared 
with HF-C L-NAME.
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LF-C LF-EAE LF-MA LF-MYR HF-C HF-EAE HF-MA HF-MYR
Emax ACh 81.5 ± 1.5 85.0 ± 2.4 79.6 ± 3.0 89.1 ± 1.8*** 64.1 ± 4.2*** 91.0 ± 3.2### 86.5 ± 3.6### 64.4 ± 3.3
Emax (L-NAME) 16.5 ± 3.2 18.4 ± 3.8 0.5 ± 2.5* 17.1 ± 5.8 13.0 ± 5.4 12.5 ± 2.1 0.5 ± 1.5### 9.4 ± 10.5
AUC ACh 183.3 ± 18.5 200.4 ± 10.3 206.9 ± 18.6 181.3 ± 10.3 147.4 ± 16.4 229.5 ± 25.3## 273.0 ± 17.8### 202.7 ± 11.7#
AUC (L-NAME) 41.5 ± 10.5 52.5 ± 17.1 15.5 ± 7.8** 62.8 ± 21.6 45.7 ± 12.8 33.9 ± 12.9 28.2 ± 3.2 64.5 ± 31.1
Table 2. Emax and AUC values from cumulative concentration curves to Ach (10-9-10-4 M) in the presence or 
not of the NO synthase inhibitor (L-NAME). Data are expressed as mean ± SEM of 5 determinations per group 
*p < 0.05, **p < 0.01, and ***p < 0.001 compared with LF-C; #p < 0.05, ##p < 0.01, and ###p < 0.001 compared with 
HF-C.
Figure 3. Cumulative concentration-response curves to phenylephrine (Phe, 10−8–10−6M) in aortic segments 
from LF and HF animals treated or not with EAE (A), MA (B), or MYR (C). Data are expressed as mean ± SEM 
of 5 determinations per group. *p < 0.05 and ***p < 0.001 compared with the LF-C group; #p < 0.05 and 
###p < 0.001 compared with the HF-C group.
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MA could be responsible, at least in part, for the effects observed with EAE. The improvement of glucose tolerance 
induced by treatment with EAE and MA was not observed when animals were treated with other compounds 
present in EAE and with a different chemical structure than MA, for example, the flavonol MYR. Therefore, we 
could discard a role for MYR in the amelioration of glucose tolerance induced by EAE in DIO mice.
Agouni et al. have suggested that PTP1B deletion improves insulin sensitivity, which directly accounts for 
the protection of endothelial function in obesity20. In this context, the second aim of this work was to assess 
if MA or EAE could improve both endothelial function and aortic insulin sensitivity in our model of DIO in 
mice. We found a significant improvement of relaxation to Ach in aortic segments from HF mice when treated 
with EAE or MA compared with the controls, which demonstrates for the first time a beneficial/protective effect 
of both EAE and MA in preventing the development of endothelial dysfunction associated with obesity. These 
results are in accordance with a study performed by Jofre et al. that described a vasodilatory effect of an extract 
of murtilla fruit in aorta from SD rats and suggested that this effect might be mediated by NO25. Similarly, within 
this study we demonstrate that the increase in Ach-induced relaxation in obese mice induced by both EAE and 
MA was also due to increased NO availability through enhancement of eNOS phosphorylation. It should be 
noted that several other compounds present in EAE like quercetin, epicatechin or MYR have shown to be able 
Figure 4. Cumulative concentration-response curves to insulin (10−10–10−5M) in aortic segments pre-
constricted with Phe from LF and HF animals treated or not with EAE (A), MA (B), or MYR (C). Data are 
expressed as mean ± SEM of 5 determinations per group. *p < 0.05 and **p < 0.01 compared with the LF-C 
group; ###p < 0.001 compared with the HF-C group.
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to induce vascular responses. Epicatechin and quercetin might exert vascular relaxation under physiologic cir-
cumstances36,37. However, a very recent study demonstrated that in overweight/obese adults, the acute intake of 
quercetin cannot improve endothelial function38. Controversial information is available regarding the vascular 
effects of myricetin, since it has been found to elicit both contractile39 and relaxant responses40, at low or high 
concentrations, respectively. In our model, MYR did not enhance Ach-induced relaxation in aortas from HF mice 
as both MA and EAE did. Therefore, we cannot discard a potential minor contribution of components other than 
MA contained in EAE on the beneficial effects elicited by the treatment with EAE on both insulin sensitivity and 
Figure 5. Confocal projections showing in situ nitric oxide (NO) availability determined with DAF-2 DA 
(10−5M, in green), nuclei staining with DAPI (in blue) and merged images in BAECs treated with EAE (40 µg/
ml) or MA (5*10−4M) with or without insulin (5*10−7M) or nothing as a control.
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endothelial function in HF mice. However, a central role for MA seems to be clear. Intriguingly, since endothelial 
function was significantly impaired in HF-C mice compared to LF-C mice due to reduced NO contribution, we 
would have expected to observe an increased contractile response to NA in HF-C mice. Nevertheless, we did 
observe significantly fewer Phe-induced contractions in HF-C mice than in LF-C animals. These results could 
suggest that the increase of sympathetic activity that has been shown to occur in obesity41 could possibly account 
for desensitization of α1-receptors, though further studies should be performed to clarify this question.
Finally, we also detected a significant improvement in insulin relaxations in aortas from HF mice treated with 
EAE, MA, or MYR compared to HF-C mice, which reveals that treatment with EAE, MA or MYR improved aortic 
insulin sensitivity. Intriguingly, and in contrast to MA and EAE that ameliorated systemic glucose tolerance in HF 
mice, MYR did not modify systemic glucose tolerance in our model of DIO. Nevertheless, Liu et al. demonstrated 
that MYR could ameliorate insulin resistance in rats fed with a high fructose diet42. Therefore, although these 
data might suggest a potential beneficial effect of MYR mainly on aortic insulin resistance, a key role for MYR 
in EAE-induced improvement of both systemic glucose tolerance and endothelial function could be discarded.
In conclusion, this study shows for the first time that EAE and one of its components, madecassic acid, could 
constitute potentially interesting candidates for the treatment of both insulin resistance and endothelial dysfunc-
tion associated with obesity.
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